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p53 in 3-D
Since its discovery in 1979 and its more
recent recognition as a significant cancer
gene, p53 has eluded researchers seeking to
construct a three-dimensional image of the
protein it encodes. Recently, a team ofscien-
tists headed by Nikola P. Pavletich at the
Sloan Kettering Memorial Hospital in New
York has achieved this goal through X-ray
crystallography and computer modeling of
the p53 protein's DNA-binding portion-
where most of its dangerous mutations
occur. The availability of this structural
information provides "a framework for
understanding how mutations mayinactivate
the p53 protein," said Pavletich. This discov-
ery may lead to the design of drugs that
reverse its cancer-causingdefects.
Role ofp53
Known as the "guardian ofthe genome," and
named 1993 "Molecule of the Year" by
Science, p53 protects human DNA. The p53
gene encodes for a tumor-suppressor protein
that provides surveillance and direction of
many cellular activities. Normal p53 is active
in control ofthe cell cycle, determiningwhen
and ifcells are replicated through interactions
with various genes and proteins. When a
piece of DNA is damaged, p53 detects the
problems and stops DNA replication, allow-
ing repair ofthe site. The p53 protein is also
thought to playa role in apoptosis, an orderly
cell suicide that occurs when a cell receives a
signal to self-destruct. Also called pro-
grammed cell death, apoptosis is a normal
process during growth and development,
helping the body to rid itself of injured or
obsolete cells. When p53 is mutated, it is
unable to perform these vital functions,
thereby allowing cancerous cells to survive
and proliferate. In fact, altered p53 proteins
are found in more than 50% ofall cancers.
Located on the short arm of human
chromosome 17, the p53 gene is subject to
mutations at almost every point of its gene
sequence. Most ofits mutations are missense
mutations, in which one DNA base is
exchanged for another. Specific environmen-
tal chemicals can cause perilous changes in
the p53 gene. Exposure to aflatoxin B1, a
food toxin endemic to areas of Asia and
Africa, causes transversions of a particular
guanosine to thymidine in the p53 sequence.
Guanosine-to-thymidine changes are often
found in cases ofhepatic cancer. Cigarette
smoke causes similar transversions through-
out the p53 gene that are found in lung and
head and neck cancers. Ultraviolet light, on
the other hand, causes
alterations in the chem-
ical bonding of cyto-
sines and thymidines.
Base-pair changes are
seen in colon and brain
cancers, as well as in
lymphomas and leu-
kemias.
While most p53
mutations occur in
somatic (body) cells and
therefore only induce
disease in the individu-
als carrying the defec-
tive gene, mutations in
germline cells (egg and
sperm) affect succeed-
ing generations. An
example of this is Li-
Fraumeni syndrome
(LFS), a mutation of
p53 associated with
soft-tissue sarcomas and
osteosarcomas. Re-
searchers are finding
that individuals who
inherit LFS are subject
to a number of differ-
ent cancers from a Crystal clear. Nikola
young age. Patients D image ofthe p53 pr
with a p53 mutation
have a 50% chance ofhaving cancer before
the age of 30 and a 90% chance before the
age of 65. Mutations of p53 may create
genetic instability, making individuals sus-
ceptible to other types ofgeneticdiseases.
The results ofmolecular genetics studies
have led to hopes of improved methods of
cancer diagnosis, prognosis, and gene-based
treatments. In the future, genetic screening
may become a routine part of a trip to the
doctor's office. Finding a defective tumor-
suppressor gene before symptoms are evident
would allow increased monitoring and early
detection of disease, which would be espe-
cially important for families affected by LFS,
for example. The presence ofa mutated p53
appears to be an important gauge ofprogno-
sis, since cancer patients with aberrant p53
genes have lower survival rates and poorer
response to treatment than patients with
normal p53 genes. In addition to increasing
the accuracy and speed ofdiagnosis, genetic
screening strategies may be applied in trials
of drugs designed to prevent cancer and
assist in choosing which chemotherapy or
radiation regimens should be used.
P. Pavletich uses X-ray crystallography to create a 3-
rotein.
Replacing a defective p53 gene through
gene therapy may provide the ideal solution
for individuals with mutations. Although
p53 gene therapy clinical trials are in
progress for patients with lung cancer at the
M.D. Anderson Cancer Center in Houston,
a number oftechnical problems still remain.
Delivering the healthyp53 genes to the right
cells and at the right place in the genetic
material, getting the newly inserted healthy
genes to produce the protein and to regulate
it properly, and making sure that insertion
of the new gene and its subsequent expres-
sion do not cause new problems are all hur-
dles thatface gene therapy.
Crystal Challenges
Elucidating p53's three-dimensional struc-
ture offered many challenges, particularly in
the science of X-ray crystallography.
Successful crystallography has three essential
components: availability of a pure protein
sample, production of a crystal of the pro-
tein, and the technology to collect and ana-
lyze X-ray diffraction data. For several
decades, scientists have been able to manipu-
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synthesize large amounts ofprotein macro-
molecules. Such efficient and rapid produc-
tion obviates the traditional painstaking iso-
lation and purification procedures that often
resulted in low quantities of protein that
were marred by contaminants. Although
molecular advances have solved the problem
ofsufficient quantity and purity, the rate-
limiting step-growing the crystals-is still a
difficult task.
InX-raycrystallography, acrystal, atight-
lypacked, highlyorganized structure ofiden-
tical, repeating copies ofa molecule, is bom-
barded with beams ofX-rays on one side at
varying angles. These beams are recorded
onto film on the other side of the crystal.
Depending on whether the beam encounters
partides (atoms) oremptyspaces inthestruc-
ture, it scatters to form characteristic patterns
on the film. Thesepatterns are measured and,
using complex mathematical equations, are
used to construct the locations and arrange-
mentsofatomswithin themolecule.
X-ray beams bounce off flat, uniform
surfaces in a measurable and predictable
manner. To visualize proteins, which have
irregular, intricately folded shapes, the pro-
teins must be in the form of a crystal. The
basic structure of a crystal, called the unit
cell, holds a certain number ofcopies ofthe
protein under study. Geometry dictates that
there are only six possible shapes for unit
cells. This makes the number of protein
copieswithin a unit cell dependent on avari-
etyoffactors, induding the type, size, electri-
cal charges, and arrangement of its amino
acids. A typical procedure used to grow crys-
tals is to supersaturate an organic solvent
with the protein and to dehydrate the solu-
tion with a crystallizing chemical agent that
forces the protein molecules to build lattice
structures. If the chemical agent is added
slowly enough to the protein solution, crys-
talsform insteadofanunorganizedresidue.
The natural properties ofproteins makes
their crystallization more tedious than crys-
tallization of salts like sodium chloride.
Biological molecules, including proteins,
form fewer bonds with their neighbors than
inorganic chemicals because of their large
size, making protein crystals relatively more
fragile. Proteins are literally forced together
by the chemical environment when forming
crystals, so the bonds that are created are
quite weak. Because proteins are very sensi-
tive to changes in temperature or solvent
conditions, they can easily lose their natural
shape and become gel-like instead ofsolid
when crystallized. "Growing crystals is not
cut and dry," says Alexander McPherson, a
crystallographer at the University of
California, Riverside. But improvements in
every aspect of the process have caused "a
burst in the number of new protein struc-
tures," headds.
Surprises andSatis&ction
The third component ofX-ray crystallogra-
phy, collection and analysis ofX-ray data,
has also taken a major leap forward since its
early days. X-ray crystallographers and struc-
tural biologists have been able to "solve"
(determine the 3-D structure of) a number
ofbiological molecules since the early 1900s.
In 1913 William Bragg worked out the ini-
tial mathematical equations by which scien-
tists determine the structure ofmolecules in
a crystal after bombardment by X-rays.
Much of these mathematics were done by
hand, with pencil and paper. Similar X-ray
techniques and calculations used by James
Watson and Francis Crick led to the discov-
eryofDNA's double helix structure in 1953.
A few years later, Max Perutz and John
Kendrew applied X-ray crystallography to
outline the structures of hemoglobin and
myoglobin, the first proteins to be solved
with X-ray crystallography. For many
decades, collecting and analyzing X-ray data
was like trying to catch one fish at a time,"
saidMcPherson.
In more recent years, crystallographers
have teamed up with computer modelers to
formulate graphics programs that assemble
3-D pictures ofproteins and DNAfragments
with the input of X-ray data. Computer
graphics also allow researchers to simulate
interactions ofaprotein with otherbiochem-
ical molecules, the possible twists and turns a
protein might endure when placed in certain
chemical environments, and the effects of
removing or changing parts of its structure.
These developments, along with improve-
ments in X-ray-generat-
ing equipment and
detection technology,
have greatly accelerated
the pace with which sci-
entists can determine
protein shapes. "Now,
new structures appear at
the rate of one per day"
saidMcPherson.
The analysis of
Pavletich's crystal revealed
a unit cell that contained
three copies of p53 pro-
tein's central region or
"core domain" attached
to a DNA fiagment. The
solution disclosed both
expected characteristics as
well as some surprises.
Unanticipated was the
uniqueness ofthe protein;
the p53 core domaindoes
not resemble structurally
any other DNA-binding
region known to date.
The amino acids of the
p53 core domain fold
into a particularly large
shape, which is unusual among proteins that
interact with DNA. The protein also displays
more predictable aspects ofa DNA-binding
protein in that it makes typical contacts along
theedgesoftheDNAhelix.
One ofmost important results from this
work is that the p53 gene's six "hot spots,"
areas of the gene that are most frequently
mutated in cancer, correspond to specific
amino acids that are altered in the protein's
core domain, said Curtis Harris at the
National Cancer Institute in Bethesda,
Maryland. This set ofmutations apparently
reduces the overall stability ofthe p53 pro-
tein-DNA complex by altering p53's struc-
ture, thus abolishing the essential contacts
made by the protein with DNA to suppress
the formationoftumors.
MolecularMedicine
Now that the protein's structure is available,
scientists "have a framework for understand-
ing how mutations may inactivate the p53
protein," said Pavletich. Such framework
may lead to procedures to reverse the
progress ofcancer.
One of the most promising applications
of this work is in drug development. "We
hope that by using the new information
about p53's structure, we may learn how to
design drugs that restore activity to mutated
p53 protein, enabling it to perform its
tumor-suppressing duties," Pavletich said.
With the aid of computer graphics,
researchers can use the 3-D image to begin
creating compounds that combine with the
p53 protein. Pharmacologists and medicinal
Pictures of the puzzle. Computer modeling of the DNA-binding portion of
p53will help scientists understand how mutations occur in this protein.
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chemists will most likely streamline their
approach to seeking drugs that will correct
altered P53; instead oftesting potential drugs
at random for their ability to bind and repair
the protein, knowledge ofthe structure may
enable some drugs to be eliminated before
commencing extensive testing.
Design ofa curative drug is not simple or
straightforward. "The 3-D structure will
greatly facilitate us in designing a drug
because it allows us to focus onto a particular
region ofthe protein," says JeffIves ofPfizer,
Inc., "but the job ahead is quite formidable."
One reason for this is the tremendous diversi-
tyofp53 mutants. Reestablishing normal p53
function will mean forcing the protein back
into its original conformation so that it can
once again make its customary contacts. In
some cases, this will involve making drugs
that block aberrant interactions between large
proteins. To correct the effects ofother muta-
tions, like those directly in the DNA-binding
area, a new drug may have to function by
obstructing the protein from regions adjacent
to the core domain. It is expected that numer-
ous types ofdrug's will be needed to correct
all mutanteffects in all types ofcancer.
Although drug developers have found
ways to correct defective enzymes and make
changes in small specific receptor sites for
certain molecules, genetic proteins represent
one of their biggest hurdles. "Whether or
not rational drug design can provide broad-
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based cancer therapeutics remains to be
seen," said Ives. "Restoration of... avirtual-
ly denatured p53 molecule will be a
Herculean task for any small [drug] mole-
cule," Stephen Friend of the Massachusetts
General Hospital Cancer Center in Boston
wrote in a recent Sciencearticle.
Equally important to cancer research is
the opportunity that scientists now have to
further understand the function of p53.
Studying a protein's structure to elucidate its
function is a standard research approach.
Andwith the increasingpossibilities for find-
ing cancer treatments, excitement in protein
crystallography is expected to continue grow-
ing. "Different mutant forms of p53 have
different bioactivities. Knowledge of the
structure gives increased insight into how
various mutations alter normal activity," said
Harris. McPherson agrees: "Getting to the
structure magnifies molecular biological
studies. In the old days, there were probably
fewer than 50 researchers worldwide trying
to grow crystals; now, there is enormous
interest in structural studies."
Janet Glover-Kerkvliet
Janet Glover-Kerkvliet is a freelance writer in
Cockeysville, Maryland.
T he American Health Foundation is an independent biomedical research organization
whose mission is research on specific environmental, nutritional and exogenous factors
causing cancer, cardiovascular disease, certain genetic diseases and aging. Synthelabo
Pharmaceuticals is a private pharmaceutical company which ranks number five in
France. In addition to conducting safety studies, one ofits primary concerns is educa-
tion in drug safety. So, with this common interest, the International Course on the Safety
Assessment ofPharmaceuticals was started in 1992.
The Course is designed for veterinarians, physicians, pharmacists and scientists ofthe pharmaceu-
tical industry in charge of nonclinical studies and those responsible for the registration of new
drugs. Participants will receive the scientific information necessary for a good comprehension of
the results ofnonclinical safety studies. Toxicologists and toxicologic pathologists may also benefit
from this course by updating their knowledge.
The Course will be held on May 7-12, 1995 at the Hilton Inn in Tarrytown, New York, which is
approximately 30 miles north of New York City. For a brochure and registration card please
contact:
Janet Marino
American Health Foundation
1 Dana Road, Valhalla, NY 10595
tel. 914/789-7140 or fax: 914/592-6317.
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